169 related articles for article (PubMed ID: 1720482)
1. Serotonin and platelet activation during treatment with isradipine.
Fetkovska N; Sebekova K; Fedelesova V; Dzurik R
J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S31-3. PubMed ID: 1720482
[TBL] [Abstract][Full Text] [Related]
2. Platelet-activating effect of low-density lipoprotein and its reversal by isradipine.
Fetkovská N; Fedelesová V; Kozlovský M; Dzúrik R
Am J Hypertens; 1991 Feb; 4(2 Pt 2):175S-177S. PubMed ID: 1827014
[TBL] [Abstract][Full Text] [Related]
3. [Inhibition of thrombocyte activity in atherogenesis and thrombogenesis using isradipine and other calcium antagonists].
Fet'kovská N; Ulicná L; Jakubovská Z
Vnitr Lek; 1993 Apr; 39(4):326-33. PubMed ID: 8351859
[TBL] [Abstract][Full Text] [Related]
4. Effects of the calcium antagonist isradipine on 24-hour ambulatory blood pressure, platelet aggregation, and neutrophil oxygen free radicals in hypertension.
Ding YA; Han CL; Chou TC; Lai WY; Shiao MF
J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S32-7. PubMed ID: 1376832
[TBL] [Abstract][Full Text] [Related]
5. Treatment of hypertension with dihydropyridine calcium antagonists and aspirin.
Tison P; Ulicna L; Jakubovska Z; Oravcova J; Fetkovska N
Blood Press Suppl; 1994; 1():57-60. PubMed ID: 8205303
[TBL] [Abstract][Full Text] [Related]
6. Platelet activation by low-density lipoprotein and serotonin: effects of calcium antagonists.
Fetkovska N
J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S25-8. PubMed ID: 1376830
[TBL] [Abstract][Full Text] [Related]
7. Isradipine increases platelet--low-density lipoprotein binding: evidence from ex-vivo studies in humans.
Schmid P; Pirich C; Fitscha P; Pesau B; Virgolini I; Sinzinger H
Blood Press Suppl; 1994; 1():65-9. PubMed ID: 8205305
[TBL] [Abstract][Full Text] [Related]
8. Platelet aggregation and metabolic control are not affected by calcium antagonist treatment in type II diabetes mellitus.
Klauser R; Speiser P; Gisinger C; Schernthaner G; Prager R
J Cardiovasc Pharmacol; 1990; 15 Suppl 1():S93-6. PubMed ID: 1695314
[TBL] [Abstract][Full Text] [Related]
9. Isradipine improves platelet function in hypertensives.
Sinzinger H; Virgolini I; Rauscha F; Fitscha P; O'Grady J
Eur J Clin Pharmacol; 1992; 42(1):43-6. PubMed ID: 1531796
[TBL] [Abstract][Full Text] [Related]
10. Metabolic, hematological, and cardiac effects of long-term isradipine treatment in mild-to-moderate essential hypertension.
Meriç M; Gören T; Atilgan D; Eren N; Cubukçu A; Koylan N
J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S58-60. PubMed ID: 1376837
[TBL] [Abstract][Full Text] [Related]
11. Serotonin metabolism and platelet aggregation under antihypertensive treatment with nitrendipine.
Sebeková K; Raucinová M; Sedláková K; Dzúrik R
J Cardiovasc Pharmacol; 1988; 12 Suppl 4():S161-3. PubMed ID: 2468865
[TBL] [Abstract][Full Text] [Related]
12. Carmoxirole inhibits platelet aggregation in vitro and ex vivo.
Kirsten R; Breidert M; Sparwasser K; Ochs JG; Hesse K; Nelson K
Int J Clin Pharmacol Ther; 1995 Feb; 33(2):76-80. PubMed ID: 7757314
[TBL] [Abstract][Full Text] [Related]
13. Effects of dihydropyridines and their combination with aspirin on blood pressure and circadian platelet activity in patients with essential hypertension.
Tison P; Ulicna L; Jakubovska Z; Oravcova J; Fetkovska N
Am J Hypertens; 1994 Jul; 7(7 Pt 2):46S-49S. PubMed ID: 7946179
[TBL] [Abstract][Full Text] [Related]
14. Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.
Amstein R; Fetkovska N; Pletscher A; Bühler FR
J Hypertens; 1989 Apr; 7(4):255-60. PubMed ID: 2723427
[TBL] [Abstract][Full Text] [Related]
15. First clinical experience with isradipine in the treatment of hypertension in Portugal.
Rocha-Gonçalves F; Mariano-Pego G; Viegas J; Correia JM; Botelho MA
J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S4-6. PubMed ID: 1720485
[TBL] [Abstract][Full Text] [Related]
16. Effects of isradipine on hypertension and renal hemodynamics.
Siamopoulos KC; Elisaf M; Dardamanis M; Sferopoulos G; Pappas M
J Cardiovasc Pharmacol; 1992; 19 Suppl 3():S87-9. PubMed ID: 1376846
[TBL] [Abstract][Full Text] [Related]
17. Platelet serotonin-LDL interaction in essential hypertension.
Amstein R; Fetkovska N; Bühler FR
J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S35-40. PubMed ID: 1717771
[TBL] [Abstract][Full Text] [Related]
18. Effects of ketanserin administration on lipid metabolism and platelet aggregation in hypertensive patients.
Loschiavo C; Valvo E; Bedogna V; Casagrande P; Graziani MS; Nicoli M; Maschio G
Int J Clin Pharmacol Ther Toxicol; 1990 Nov; 28(11):455-7. PubMed ID: 2272704
[TBL] [Abstract][Full Text] [Related]
19. [In vivo platelet activation in mild arterial hypertension].
Guicheney P; Baudouin-Legros M; Meyer P
Arch Mal Coeur Vaiss; 1987 Jun; 80(6):808-11. PubMed ID: 2959230
[TBL] [Abstract][Full Text] [Related]
20. Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group.
Jern S; Hansson L; Scherstén B; Kullman S; Sörensen S; Dahlöf B; Eggertsen R; Sivertsson R
J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S7-8. PubMed ID: 1720487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
